Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Sells $12,000.00 in Stock

by · The Cerbat Gem

Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report) CEO Todd Harris sold 500 shares of the firm’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $24.00, for a total value of $12,000.00. Following the sale, the chief executive officer now owns 1,477,373 shares in the company, valued at approximately $35,456,952. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Todd Harris also recently made the following trade(s):

  • On Wednesday, September 25th, Todd Harris sold 600 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.01, for a total transaction of $14,406.00.
  • On Monday, September 23rd, Todd Harris sold 10,092 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.13, for a total transaction of $243,519.96.
  • On Thursday, September 19th, Todd Harris sold 5,698 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.31, for a total transaction of $138,518.38.

Tyra Biosciences Price Performance

TYRA stock opened at $22.04 on Friday. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of -13.12 and a beta of 1.01. Tyra Biosciences, Inc. has a 1-year low of $10.38 and a 1-year high of $25.14. The firm has a fifty day moving average price of $21.79 and a two-hundred day moving average price of $19.03.

Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.09. As a group, analysts expect that Tyra Biosciences, Inc. will post -1.53 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on TYRA shares. Oppenheimer boosted their price target on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, September 19th. Piper Sandler began coverage on shares of Tyra Biosciences in a research note on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $23.00 price objective on shares of Tyra Biosciences in a research note on Wednesday, July 3rd. Finally, Wedbush reaffirmed an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a research report on Thursday, August 8th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Tyra Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $26.40.

Read Our Latest Stock Report on Tyra Biosciences

Institutional Trading of Tyra Biosciences

Hedge funds have recently made changes to their positions in the stock. Oppenheimer & Co. Inc. acquired a new position in shares of Tyra Biosciences during the first quarter valued at $977,000. Vanguard Group Inc. grew its position in Tyra Biosciences by 18.6% in the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock worth $14,757,000 after purchasing an additional 140,833 shares during the last quarter. Kynam Capital Management LP acquired a new stake in shares of Tyra Biosciences in the fourth quarter valued at approximately $4,712,000. American Century Companies Inc. raised its holdings in shares of Tyra Biosciences by 582.9% during the second quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock valued at $2,723,000 after buying an additional 145,346 shares during the last quarter. Finally, Perceptive Advisors LLC raised its holdings in shares of Tyra Biosciences by 50.5% during the second quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after buying an additional 338,208 shares during the last quarter. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

(Get Free Report)

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

Read More